Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jacob Hooker
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Eikonizo Therapeutics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The company is pursuing drug development for neurodegenerative diseases based on HDAC6 inhibition. The research seeks to develop an HDAC6 PET radiotracer which will be able to provide quantitative maps of HDAC6 in the human brain and accelerate the development of neurodegenerative disease therapies based on HDAC6 inhibition. The research evaluates an HDAC6 small molecule which the company may license. The results of this study could therefore be of interest to the company. The Partners Committee on Outside Activities review panel evaluated the financial interest in connection with this research project and determined that, based on the close connection between the company’s interests and the research, and the type and level of the SFI, the SFI is related to the research and could directly and significantly affect the design, conduct, or reporting of the research.
Epigenetic Radiotracers for PET Imaging: Isoform-SelectiveHDAC Probes
Project Narrative Although homologous to other histone deacetylases (HDACs), the isoform named HDAC6 regulates the acetylation state of distinct non-histone proteins and when chemically inhibited has shown efficacy in animal models of mood disorders, neurodegenerative diseases and certain cancers. Currently, there are no tools for determining HDAC6 density and dysregulation in the living human brain. The development of an HDAC6 radiotracer for use in positron emission tomography will provide quantitative maps of HDAC6 in the human brain and will accelerate the development of therapies based on HDAC6 inhibition.
Filed on December 19, 2017.
Tell us what you know about Jacob Hooker's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Jacob Hooker”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jacob Hooker | Massachusetts General Hospital | Conflict of Interest | Eikonizo Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.